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We designed a phase I/II trial of S-1 combined with weekly docetaxel to determine the maximum tolerated dose (MTD) and
recommended dose (RD) and to evaluate the efficacy and toxicity in metastatic gastric carcinoma (MGC). Patients with measurable
disease received S-1 orally b.i.d. on days 1–14 and docetaxel intravenously on days 1 and 8 every 3 weeks. In phase I (n¼30), each
cohort received escalating doses of S-1 (30–45mgm
 2 b.i.d.) and docetaxel (25–40mgm
 2); MTD was 45mgm
 2 b.i.d. S-1/
35mgm
 2 docetaxel and RD was 40mgm
 2 b.i.d. S-1/35mgm
 2 docetaxel. Dose-limiting toxicities included grade 3 elevated liver
enzymes, gastric perforation, grade 3 diarrhoea/fatigue, febrile neutropenia with grade 3 anorexia/fatigue, and neutropenic infection
with grade 3 stomatitis/anorexia. In phase II (n¼52), the overall response rate was 66.7% (95% confidence interval (CI): 53.8–79.6%)
and the median time to progression and overall survival were 6.5 months (95% CI: 4.9–8.1) and 13.7 months (95% CI: 9.9–17.5),
respectively. The most common grade 3/4 toxicity was neutropenia (29.4%), and febrile neutropenia/neutropenic infection occurred
in 19.6% of patients. Non-haematological toxicities were generally mild. There was one treatment-related death due to pneumonitis.
S-1 combined with weekly docetaxel is active in MGC with moderate toxicities.
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Despite its decreasing incidence over the past few decades, gastric
cancer remains one of the major cause of death due to cancer
worldwide (Parkin et al, 2005). Survival benefits have been
demonstrated by systemic chemotherapy in patients with locally
advanced or metastatic gastric carcinoma (MGC) (Pyrhonen et al,
1995; Glimelius et al, 1997); however, the results of most
combination regimens have been unsatisfactory, with median
survival times of 6–9 months (Webb et al, 1997; Vanhoefer et al,
2000; Ohtsu et al, 2003). To date, the most commonly used
combination chemotherapies have been based on fluorouracil
(5-FU) and/or cisplatin, with 5-FU/cisplatin (FP) and epirubicin/
cisplatin/5-FU being currently regarded as reference treatments.
Although a recent phase III trial showed that patients treated with
docetaxel combined with FP had superior survival to patients
treated with FP alone, the former regimen also had severe
toxicities, thereby limiting its application (Van Cutsem et al,
2006). In addition, cisplatin-based chemotherapy is frequently
associated with an unfavourable toxicity profile, including severe
emesis, neurotoxicity, and nephrotoxicity. Continuous intravenous
infusion of 5-FU also results in inconvenience to patients and
catheter-related complications. Therefore, there is a need to
develop active, but less-toxic, chemotherapy regimens, which
include new active compounds.
S-1 is a novel oral fluoropyrimidine, consisting of tegafur,
5-chloro-2,4-dihydroxypyridine, a dihydropyrimidine dehydro-
genase inhibitor, and potassium oxonate, which inhibits orotate
phosphoribosyl transferase in the gastrointestinal tract, thereby
suppressing gastrointestinal toxicity caused by the phosphoribo-
sylation of 5-FU (Shirasaka et al, 1996). S-1 has demonstrated
significant activity in advanced gastric cancer, achieving response
rates of 26–49% with good safety profiles in several phase II trials
(Sakata et al, 1998; Koizumi et al, 2000; Chollet et al, 2003).
Docetaxel, which inhibits microtubule depolymerisation, has
been widely used in the treatment of MGC, with response rates of
16–24% when used as a single agent in phase II trials (Sulkes et al,
1994; Bang et al, 2002). Compared with the 3-weekly regimen,
docetaxel administered once weekly has a favourable safety profile,
including myelosuppression (Schuette et al, 2005; Bria et al, 2006;
Camps et al, 2006).
Due to the activity of S-1 and docetaxel in MGC, and their
synergistic activity in gastric cancer cell lines and xenografts
(Takahashi et al, 2005; Wada et al, 2006), we designed a phase I/II
trial of S-1 combined with weekly docetaxel in patients with MGC
to determine the maximum tolerated dose (MTD) and recom-
mended dose (RD) of these agents when used together, and to
evaluate their efficacy and toxicity.
PATIENTS AND METHODS
Eligibility
Patients were eligible for this trial if they were over 18 years of
age with histologically proven MGC, unidimensionally measurable
disease, an ECOG (Eastern Cooperative Oncology Group)
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sperformance status of 0–2, and possessed adequate baseline
haematological function (ANC (absolute neutrophil count)
X1.5 10
9l
 1, platelet count X100 10
9l
 1), hepatic function
(serum aspartate aminotransferase and alanine aminotransferase
p2.5 times ULN (upper limit of normal) and serum bilirubin
pULN), and renal function (serum creatinine pULN). Patients in
the phase II part had received no prior chemotherapy, including
adjuvant chemotherapy, whereas patients in the phase I part were
permitted up to two previous chemotherapy regimens, except for
prior taxane or S-1, and were required to have discontinued
chemotherapy for at least 4 weeks before participating in this
study.
Patients were excluded if they had a history of other
malignancies within the previous 3 years, had severe comorbid
conditions, or lacked the ability to comply with the requirements
of the protocol. Patients receiving drugs with potential interactions
with S-1 (e.g., flucytosine, allopurinol, and phenytoin) were also
excluded. All patients provided written informed consent, and the
protocol was approved by our Institutional Review Board.
Pretreatment evaluations
Baseline evaluations included medical history, physical examina-
tion, ECOG performance status, complete blood cell count, serum
chemistries and electrolytes, urinalysis, urine pregnancy test (for
women), 24-h urine creatinine clearance, chest X-ray, computed
tomography, electrocardiogram, and recording of concomitant
medications.
Treatment and study design
During each 3-week cycle, patients received oral S-1 twice daily
(within 1h after morning and evening meals) on days 1–14 and a
1h intravenous infusion of docetaxel on days 1 and 8. All the
patients received oral dexamethasone (4mg twice daily for 4 doses,
starting 12h before docetaxel) and parenteral pheniramine maleate
(45.5mg) prophylactically. Prophylactic administration of granu-
locyte colony-stimulating factor and antiemetics was not allowed;
however, secondary prophylaxis or therapy with antiemetics in
subsequent cycles was allowed. Treatment was continued in the
absence of disease progression or unacceptable toxicity for a
maximum of 12 cycles.
During phase I, each cohort of at least three patients was treated
with escalating doses of S-1/docetaxel: 30mgm
 2 b.i.d./25mgm
 2
(level 1), 35mgm
 2 b.i.d./25mgm
 2 (level 2), 35mgm
 2 b.i.d./
30mgm
 2 (level 3), 40mgm
 2 b.i.d./30mgm
 2 (level 4),
40mgm
 2 b.i.d./35mgm
 2 (level 5), 45mgm
 2 b.i.d./35mgm
 2
(level 6), and 45mgm
 2 b.i.d./40mgm
 2 (level 7). Dose escalation
was continued until at least one-third of the patients in a given
cohort showed dose-limiting toxicity (DLT) during the first cycle.
Before escalating to the next dose level, all three patients should
have received at least one treatment cycle. If none of the first three
treated patients developed DLT during the first cycle at a specific
dose level, dose escalation was continued. If one out of the first
three treated patients developed DLT at any dose level, three
additional patients were entered at the same dose level; if only one
in six patients at a given level experienced a DLT, dose escalation
was continued. The MTD was defined as the dose level at which
one-third or more of patients experienced a DLT. The RD for the
subsequent phase II study was defined as the dose level preceding
the attainment of the MTD.
Dose-limiting toxicity was defined as any of the following: (1)
grade 4 neutropenia lasting at least 7 days; (2) grade 3/4
neutropenia associated with infection or fever (X38.31C as single
temperature or X38.01C for 1h); (3) grade 3 thrombocytopenia
with grade 3/4 haemorrhage; (4) grade 4 thrombocytopenia; (5)
grade 3/4 non-haematological toxicity other than alopecia or
nausea/vomiting relieved by antiemetic therapy; (6) grade 3/4
nausea/vomiting not reduced to grade p1 with aggressive
antiemetic support; or (7) inability of the patient to take X75%
of the planned chemotherapy dose during the treatment period.
Phase II was performed using the RD determined during phase I.
Dose modifications
The next chemotherapy cycle was delayed if patients had ANC
o1.5 10
9l
 1, platelet count o100 10
9l
 1, or any grade 41
non-haematological toxicity, excluding alopecia. Docetaxel dose
was reduced by 20% in subsequent cycles if patients experienced
grade 3/4 neutropenia associated with infection or fever (X38.31C
as single temperature or X38.01C for 1h), grade 4 thrombocyto-
penia, grade 3 non-haematological toxicity, grade 2/3 neurological
toxicity, or recurrent fluid retention. Docetaxel treatment on day
8 was delayed to day 10 for ANC o1.5 10
9l
 1, platelet count
o75 10
9l
 1, or grade X2 non-haematological toxicity on the
day of scheduled treatment. On day 10, docetaxel dose was reduced
by 50% for ANC of 0.5 10
9l
 1–1.0 10
9l
 1 or platelet count of
50 10
9l
 1–75 10
9l
 1, and omitted for other toxicities. S-1 dose
was reduced by 20% in subsequent cycles if patients experienced
grade 3/4 neutropenia associated with infection or fever, grade
4 thrombocytopenia, a second occurrence of a grade 2 non-
haematological toxicity, or any grade 3 non-haematological
toxicity. If patients experienced a grade 4 non-haematological
toxicity, docetaxel and S-1 were definitively interrupted or
continued at doses 50% less than the starting dose.
Evaluation during chemotherapy
During phase I, complete blood cell count and serum chemistries
were monitored twice weekly and once weekly, respectively, during
the first cycle, except for the first week and on days 1 and 8 of each
subsequent cycle. During phase II, complete blood cell count and
serum chemistries were monitored weekly during the first two
cycles and on days 1 and 8 of each subsequent cycle.
Assessment of efficacy and toxicity
Computed tomography scans were performed every two cycles to
evaluate the tumour response, which was assessed according to the
Response Evaluation Criteria in Solid Tumors (Therasse et al,
2000). Objective responses were confirmed by a second evaluation
4–6 weeks later. Time to progression (TTP) was calculated from
the date of first chemotherapy cycle to the date of disease
progression, and overall survival (OS) was calculated from the date
of first chemotherapy cycle to either the date of death due to any
cause or the date of the last follow-up visit. Toxicity was graded
according to the National Cancer Institute Common Toxicity
Criteria (version 2.0).
Phase II study: statistical planning and analysis
The primary end point for the phase II part of the study was the
objective response rate, and the secondary endpoints were TTP,
OS, and safety. A two-stage optimal design proposed by Simon was
used to determine the sample size of phase II (Simon, 1989).
Assuming P0¼0.3, P1¼0.5, with a¼0.05 and b¼0.2, the first
stage required at least 6 out of 15 patients to have a response
before proceeding to the second stage. An additional 31 assessable
patients were to be enrolled; if 19 or more out of the 46 assessable
patients would have a response, the treatment would be considered
sufficiently active. Assuming that 10% of patients could not be
evaluated, the planned sample size of the phase II part was 52
patients. The parameters TTP and OS were estimated using the
Kaplan–Meier method.
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Phase I
Patient characteristics A total of 30 patients, of median age 50
years (range: 22–71) entered phase I from September 2004 to
September 2005. Six patients entered at dose level 1, three each at
dose levels 2–4, six each at dose levels 5 and 6, and three at dose
level 7. Patient characteristics are summarised in Table 1. Most
patients had an ECOG performance status of 1 (93.3%) and
multiple metastases involving two or more organ systems (86.7%).
All patients had metastatic disease; three had recurrent disease and
had received prior adjuvant chemotherapy (5-FU plus mitomycin
C). Another patient had received adjuvant doxifluridine and
radiotherapy for resected pancreatic cancer 5 years earlier.
Dose-limiting toxicity, maximum tolerated dose, and recommended
dose Chemotherapy toxicities per patient including DLTs during
the first cycle are summarised in Table 2. At dose level 1
(30mgm
 2 b.i.d. S-1 plus 25mgm
 2 docetaxel), one of the first
three patients experienced a DLT (grade 3 aspartate aminotrans-
ferase elevation) but none of the three additional patients
experienced a DLT. During dose escalation, DLT did not develop
until dose level 7 (45mgm
 2 b.i.d. S-1 plus 40mgm
 2 docetaxel),
at which two out of three patients experienced DLTs (grade 3
febrile neutropenia and grade 3 infection with neutropenia with
grade 3 stomatitis/anorexia). Therefore, the next three patients
were entered at dose level 6 (45mgm
 2 b.i.d. S-1 plus 35mgm
 2
docetaxel), but two of these patients (two out of six) had DLTs
(grade 3 diarrhoea with grade 3 fatigue and febrile neutropenia
with grade 3 anorexia/fatigue). An additional three patients were
entered at dose level 5 (40mgm
 2 b.i.d. S-1 plus 35mgm
 2
docetaxel), but one (one out of six) experienced a DLT (gastric
perforation at the tumour site on the first day of the first cycle).
Therefore, level 6 was considered as the MTD and level 5 was
defined as the RD for the ensuing phase II study.
Phase II
Patient characteristics From October 2005 to July 2006, 52
patients were enrolled in the phase II study: 38 (73.1%) males
and 14 (26.9%) females of median age 53 years (range: 23–70).
Most of the patients (94.2%) had an ECOG performance status of 1,
and 45 (86.5%) had multiple metastases involving two or more
organ systems. Metastatic sites included the abdominal lymph
nodes (94.2%), peritoneum (50.0%), liver (34.6%), and others
(25.0%) (Table 1). All patients had metastatic disease, with three
having recurrent disease after prior subtotal gastrectomy.
Efficacy Out of the 52 patients, 51 could be evaluated for
response, whereas 1 patient was lost to follow-up after day 1 of the
first chemotherapy cycle. Two patients (3.9%) achieved complete
response and 32 (62.7%) had partial response, making the overall
response rate 66.7% (95% confidence interval (CI): 53.8–79.6%).
Table 1 Patient characteristics
Characteristic Phase I Phase II
No. of patients 30 52
Median age in years (range) 50 (27–71) 53 (23–70)
Gender
Male 20 (66.7%) 38 (73.1%)
Female 10 (33.3%) 14 (26.9%)
ECOG performance status
0 2 (6.7%) 3 (5.8%)
1 28 (93.3%) 49 (94.2%)
Metastatic organ site
Abdominal lymph node 25 (83.3%) 49 (94.2%)
Peritoneum 19 (63.3%) 26 (50.0%)
Liver 8 (26.7%) 18 (34.6%)
Others 14 (46.7%) 13 (25.0%)
No. of metastatic organ sites
1 4 (13.3%) 7 (13.5%)
2 17 (56.7%) 23 (44.2%)
X3 9 (30.0%) 22 (42.3%)
Prior treatment
Total gastrectomy 1 (3.3%) 0 (0%)
Subtotal gastrectomy 2 (6.7%) 3 (5.8%)
Adjuvant 5-FU+MMC 3 (10.0%) 0 (0%)
Adjuvant doxifluridine+RT 1 (3.3%) 0 (0%)
ECOG¼Eastern Cooperative Oncology Group; 5-FU¼5-fluorouracil;
MMC¼mitomycin C; RT¼radiotherapy.
Table 2 Toxicities at various dose levels of S-1 and docetaxel during the first cycle of phase I
Dose
a of S-1 and docetaxel
30/25 (n¼6) 35/25 (n¼3) 35/30 (n¼3) 40/30 (n¼3) 40/35 (n¼6) 45/35 (n¼6) 45/40 (n¼3)
Toxicity (NCI-CTC) G1/2 G3/4 G1/2 G3/4 G1/2 G3/4 G1/2 G3/4 G1/2 G3/4 G1/2 G3/4 G1/2 G3/4
Anaemia 4 1 3 0 2 0 2 0 4 0 6 0 3 0
Leukopenia 2 0 1 0 2 0 2 0 3 0 3 1 1 2
Neutropenia 2 0 0 1 0 1 2 0 2 0 2 2 0 3
Thrombocytopenia 0 0 0 0 0 0 0 0 0 0 0 0 1 0
Febrile neutropenia/neutropenic infection — 0 — 0 — 0 — 0 — 0 — 1 — 2
Diarrhoea 2 0 1 0 1 0 1 0 4 0 2 1 3 0
Stomatitis 2 0 0 0 1 0 2 0 2 0 4 0 2 1
Nausea
b 30301010303020
Vomiting
b 10000010001010
Anorexia 3 0 2 0 3 0 2 0 5 0 5 1 2 1
Fatigue 1 0 1 0 1 0 3 0 4 0 4 2 3 0
Elevated AST/ALT 2 1 0 0 1 0 0 0 2 0 0 0 0 0
Gastric perforation 0 0 0 0 0 0 0 0 0 1 0 0 0 0
ALT¼alanine aminotransferase; AST¼aspartate aminotransferase; NCI-CTC¼National Cancer Institute Common Toxicity Criteria.
aOne dose of S-1 and docetaxel; for
example, 30/25 means 30mgm
 2 S-1 twice on days 1–14 and 25mgm
 2 docetaxel on days 1 and 8.
bProphylactic administration of antiemetics was not allowed during the
first cycle.
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progressive disease. All objective responses were confirmed by
follow-up computed tomography at least 4 weeks after the initial
documentation of response. The median duration of response was
6.3 months (range: 1.6 to 13.8þ). The median follow-up time was
13.1 months (range: 8.5–18.0), during which the median TTP was
6.5 months (95% CI: 4.9–8.1 months) (Figure 1) and the median
OS was 13.7 months (95% CI: 9.9–17.5) (Figure 2). The one-year
survival rate was 58.5% (95% CI: 44.2–72.8%).
Treatment delivered A total of 385 cycles were administered, with
a median of 8 per patient (range: 1–12). Treatment was delayed for
a median of 6 days (range: 4–28) in 70 cycles (18.2%) in 43
patients (82.7%), mainly because of grade 2–4 neutropenia (11
cycles), infection without neutropenia (10 cycles), grade 2
stomatitis (7 cycles), febrile neutropenia/infection with neutro-
penia (5 cycles), and abnormal liver function test (5 cycles).
Seventeen cycles were delayed due to reasons unrelated to disease
or treatment, including pending imaging studies to evaluate
response or at the patient’s request. Dose reduction of S-1 was
required in 148 (38.4%) cycles in 27 patients (51.9%), primarily
due to febrile neutropenia/infection with neutropenia (51 cycles),
grade 3 or recurrent grade 2 stomatitis (36 cycles), grade 3 or
recurrent grade 2 fatigue (14 cycles), grade 3 or recurrent grade 2
diarrhoea (12 cycles), grade 3 infection without neutropenia (9
cycles), and recurrent grade 2 abdominal pain (7 cycles). Dose
reduction of docetaxel was required in 100 cycles (26.0%) in 18
patients (34.6%), primarily due to febrile neutropenia/infection
with neutropenia (51 cycles), grade 3 fatigue (13 cycles), grade 3
infection without neutropenia (9 cycles), grade 3 stomatitis (7
cycles), and grade 3 diarrhoea (7 cycles). The relative dose
intensities of S-1 and docetaxel were 85.6% (319.5mgm
 2 per
week) and 91.8% (21.4mgm
 2 per week), respectively.
The reasons for discontinuation of treatment were disease
progression (n¼32, 61.5%), adverse events (n¼3, 5.8%) (one
patient each with grade 4 docetaxel-induced pneumonitis, grade 4
pneumonia, and grade 3 peripheral neuropathy), loss to follow-up
(n¼3, 5.8%), and patient refusal (n¼3, 5.8%). The remaining 11
patients finished the planned maximum of 12 cycles of
chemotherapy; 8 of these patients are currently being followed
without chemotherapy, whereas 3 had disease progression while
off chemotherapy.
Toxicity Fifty-one patients were assessable for toxicity. Table 3
summarises chemotherapy toxicities per patient. The most
common grade 3/4 haematological toxicities were neutropenia
(29.4% of patients) and leukopenia (29.4%). Grade 3/4 febrile
neutropenia and grade 3 infection with neutropenia each occurred
in five patients (9.8%). All these patients were successfully treated
with antibiotics and granulocyte colony-stimulating factor. Grade
3 anaemia occurred in three patients (5.9%), but no patient
experienced grade 3/4 thrombocytopenia.
Non-haematological toxicities were generally mild-to-moderate
and manageable. Grade 4 non-haematological toxicity occurred in
only one patient (2.0%) who experienced docetaxel-induced
pneumonitis and died of this disease. The most common grade 3
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Figure 1 Time to progression for all evaluable patients in phase II
(n¼51).
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Figure 2 Overall survival for all eligible patients in phase II (n¼52).
Table 3 Toxicity of chemotherapy in phase II (n¼51)
No. of patients (%)
Toxicity (NCI-CTC) Grade 1 Grade 2 Grade 3 Grade 4
Haematological
Leukopenia 14 (27.5) 7 (13.7) 12 (23.5) 3 (5.9)
Neutropenia 13 (25.5) 8 (15.7) 9 (17.6) 6 (11.8)
Febrile neutropenia/
infection with neutropenia
— — 9 (17.6) 1 (2.0)
Anaemia 22 (43.1) 25 (49.0) 3 (5.9) 0 (0)
Thrombocytopenia 2 (3.9) 0 (0) 0 (0) 0 (0)
Non-haematological
Stomatitis 20 (39.2) 21 (41.2) 3 (5.9) 0 (0)
Anorexia 24 (47.1) 24 (47.1) 1 (2.0) 0 (0)
Nausea 20 (39.2) 16 (31.4) 1 (2.0) —
Vomiting 16 (31.4) 9 (17.6) 0 (0) 0 (0)
Diarrhoea 25 (49.0) 12 (23.5) 2 (3.9) 0 (0)
Constipation 14 (27.5) 1 (2.0) 3 (5.9) 0 (0)
Fatigue 24 (47.1) 19 (37.3) 5 (9.8) 0 (0)
Tearing 19 (37.3) 22 (43.1) 0 (0) —
Alopecia 21 (41.2) 30 (58.8) — —
Oedema 38 (74.5) 6 (11.8) 0 (0) 0 (0)
Skin rash 12 (23.5) 5 (9.8) 0 (0) 0 (0)
Nail changes 16 (31.4) 22 (43.1) — —
Hand-foot syndrome 5 (9.8) 2 (3.9) 1 (2.0) —
Pneumonitis 0 (0) 0 (0) 1 (2.0) 1 (2.0)
Peripheral neuropathy 34 (66.7) 3 (5.9) 1 (2.0) 0 (0)
AST/ALT elevation 15 (29.4) 5 (9.8) 2 (3.9) 0 (0)
Hyperbilirubinemia 6 (11.8) 4 (7.8) 0 (0) 0 (0)
Infection without neutropenia 0 (0) 11 (21.6) 8 (15.7) 0 (0)
ALT¼alanine aminotransferase; AST¼aspartate aminotransferase; NCI-CTC¼
National Cancer Institute Common Toxicity Criteria.
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(n¼8, 15.7%): pneumonia (n¼4), periungal infection (n¼2),
cellulitis (n¼1), and urinary tract infection (n¼1). Other grade 3
non-haematological toxicities were grade 3 fatigue (9.8% of
patients), stomatitis (5.9%), constipation (5.9%), diarrhoea
(3.9%), aspartate aminotransferase/alanine aminotransferase
elevation (3.9%), anorexia (2.0%), nausea (2.0%), peripheral
neuropathy (2.0%), hand-foot syndrome (2.0%), and docetaxel-
induced pneumonitis (2.0%).
Second-line chemotherapy During the follow-up period, 36
(69.2%) out of the 52 patients received second-line chemotherapy:
17 received irinotecan/cisplatin, 8 received oxaliplatin/5-FU/
leucovorin, 3 received irinotecan/5-FU/leucovorin, 3 received
capecitabine/cisplatin, and 5 received other regimens. Out of these
36 patients, 34 were evaluable for efficacy, 9 (26.5%) achieved a
partial response, 10 (29.4%) had stable disease, and 15 (44.1%)
showed progression. The median TTP of second-line chemotherapy
was 2.8 months (95% CI: 2.0–3.6).
DISCUSSION
We have shown here that S-1 combined with weekly docetaxel is a
highly active first-line chemotherapy regimen for MGC. The
overall response rate of 66.7%, median TTP of 6.5 months, and
median OS of 13.7 months are comparable to results of trials using
older (Webb et al, 1997; Vanhoefer et al, 2000; Ohtsu et al, 2003) or
newly developed chemotherapeutic agents (Roth et al, 2000;
Ridwelski et al, 2001; Al-Batran et al, 2004; Bouche et al, 2004;
Park et al, 2004; Chun et al, 2005; Kim et al, 2005; Moehler et al,
2005; Giordano et al, 2006; Kang et al, 2006; Orditura et al, 2006;
Van Cutsem et al, 2006), including oxaliplatin, irinotecan,
capecitabine, and other docetaxel-containing regimens. With the
latter agents, response rates ranged from 9 to 60%, median TTP
from 1.9 to 6.9 months, and median OS from 5.7 to 12.0 months
(Roth et al, 2000; Ridwelski et al, 2001; Al-Batran et al, 2004;
Bouche et al, 2004; Park et al, 2004; Chun et al, 2005; Kim et al,
2005; Moehler et al, 2005; Giordano et al, 2006; Kang et al, 2006;
Orditura et al, 2006; Van Cutsem et al, 2006).
Recently, phase III trials of S-1 alone and/or S-1 combined with
cisplatin showed that S-1 alone had non-inferior OS compared
with infusional 5-FU (11.4 vs 10.8 months, non-inferiority
Po0.001), and then S-1 combined with cisplatin had superior
OS to S-1 alone (13.0 vs 11.0 months, P¼0.0366) (Boku et al, 2007;
Narahara et al, 2007). Considering the potential of the S-1-based
combination regimen, the combination of S-1 and the new
cytotoxic agent in the present study deserves comparison in
further phase III trials.
During phase I of our trial, we determined that the RD and
treatment schedule for phase II was 40mgm
 2 b.i.d. S-1 on days
1–14 and 35mgm
 2 docetaxel on days 1 and 8 of each 3-week
cycle. Two recent trials of S-1 combined with docetaxel used
different doses and schedules; the first used 40mgm
 2 S-1 b.i.d. on
days 1–14 and 40mgm
 2 docetaxel on day 1 of each 3-week cycle
(Yoshida et al, 2006), and the second used 40mgm
 2 b.i.d. S-1 on
days 1–14 and 40mgm
 2 docetaxel on day 1 of each 4-week cycle
(Yamaguchi et al, 2006). Despite these variations, the DLTs in
phase I of these trials included neutropenia and complicated
neutropenia, similar to our trial (Yoshida et al, 2004; Yamaguchi
et al, 2006). Although a direct comparison between other phase II
trials and our trial is difficult, one previous trial, which had the
same planned dose intensity of S-1 and a different dose intensity of
docetaxel as our trial, showed similar efficacy, with an overall
response rate of 56.3% (compared with 66.7% in our trial), a
median TTP of 7.3 months (compared with 6.5 months), and a
median OS of 14.3 months (compared with 13.7) (Yoshida et al,
2006). About 10% of patients in this trial, however, had locally
advanced disease, whereas all of our patients had metastatic
disease (Yoshida et al, 2006). Moreover, the patients in this trial
received a median of four cycles (in a 3-week cycle) and had a
median response duration of only 5.1 months (Yoshida et al,
2006). This discrepancy between the relatively low number of
median treatment cycles per patient and long median TTP may not
be usual treatment outcomes. In our study, patients received a
median eight cycles of chemotherapy and had a median response
duration of 6.3 months. Another previous trial, which used a lower
dose intensity (40mgm
 2 b.i.d. S-1 on days 1–14 and 40mgm
 2
docetaxel on day 1 of each 4-week cycle) compared with our trial,
showed inferior efficacy, with an overall response rate of 46% and
a median progression-free survival of 4.1 months (Yamaguchi
et al, 2006). It may be attributed to the weekly regimen that a
higher dose of docetaxel could be determined as RD in our trial
than in previous two trials; docetaxel administered once weekly
has lower toxicity with comparable efficacy compared with the 3-
weekly regimen (Schuette et al, 2005; Bria et al, 2006; Camps et al,
2006).
The regimen used in the present trial resulted in a generally
low incidence of grade 3/4 haematological toxicities, including
neutropenia (29.4%), and non-haematological toxicities.
Febrile neutropenia and infection with neutropenia, however,
occurred in a relatively high proportion of patients (19.6%).
This may be related to the relatively high incidence of grade
1/2 stomatitis (80.4%) and diarrhoea (72.5%), in that disruption
of the mucosal barrier may make patients susceptible to infection.
This high incidence of grade 1/2 non-haematological toxicities
may be associated with the long treatment duration, a median of
eight cycles per patient. Due to the frequency of febrile
neutropenia or infection with neutropenia and the actual dose
intensity of S-1 and docetaxel in phase II of our trial, we propose
that the RD of this regimen be lowered to 35mgm
 2 b.i.d. S-1 on
days 1–14 and/or 30mgm
 2 docetaxel on days 1 and 8 of each
3-week cycle, or prophylactic granulocyte colony-stimulating
factor be used.
Notably, this regimen resulted in a low incidence of nausea
and vomiting despite the absence of primary prophylactic
antiemetics. Grade 2 nausea and vomiting occurred in 31.4
and 17.6% of patients, respectively, and grade 3 nausea developed
in only one patient (2.0%). During the entire treatment
period, only 19 patients (36.5%) in 49 cycles (12.7%) were
given a serotonin antagonist for secondary prophylaxis during
subsequent cycles or therapy. The current regimen compares
favourably with cisplatin, irinotecan, oxaliplatin, or infusional
5-FU-containing regimens, in which the incidence of grade 3/4
nausea/vomiting ranged from 4.9 to 26% with prophylactic
antiemetics (Webb et al, 1997; Roth et al, 2000; Vanhoefer et al,
2000; Ridwelski et al, 2001; Ohtsu et al, 2003; Al-Batran et al, 2004;
Bouche et al, 2004; Moehler et al, 2005; Kang et al, 2006; Van
Cutsem et al, 2006).
This regimen also resulted in a very low incidence of grade 2/3
hand-foot syndrome (5.9%), which is quite troublesome and has
been reported to occur in 12.9% to more than 50% of patients
treated with capecitabine, another oral fluoropyrimidine, com-
bined with docetaxel (Park et al, 2004; Chun et al, 2005; Kim et al,
2005; Giordano et al, 2006).
Taken together, we conclude that S-1 combined with weekly
docetaxel is a highly active outpatient regimen in MGC with
moderate toxicity. Further studies with appropriate dose modi-
fications are warranted.
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